



# 3<sup>rd</sup> IVF Worldwide Online Congress: Optimizing IVF treatment to maximize the likelihood of conception

14:00-22:00 CEST

## PRELIMINARY PROGRAM

<b>Friday, April 2, 2021</b>	
Welcome notes: <b>Zeev Shoham</b> , Israel, <b>Milton Leong</b> , Hong Kong	
<b>14:00- 15:40</b>	<b>Session 1: Opening / New innovation in Reproductive Medicine</b> <i>Supported by Abbott</i>
Innovative methods and cutting edge technologies in the laboratory that will impact the patient journey <b>Denny Sakkas</b> , USA	
Home fertility care <b>John Zhang</b> , USA	
Embryo culture: Past present and future <b>David Gardner</b> , Australia	
Discussion	
<b>15:40-16:30</b>	<b>Session 2: New innovation in Reproductive Medicine</b>
Making oocytes from skin biopsy in humans: The eight genes needed to go directly from IPS cell to oocyte, and how we can make fetal granulose cells similarly from just a few growth factors. <b>Sherman Silber</b> , USA	
Detection of balanced rearrangements in embryos – comprehensive PGT-SR <b>Svetlana Madjunkova</b> , Canada	
Discussion	
<b>16:30-17:45</b>	<b>Session 3: The future is here: Starting the journey with AI based embryo evaluation</b> <i>Supported by an unrestricted educational grant by Vitrolife</i>
Standardizing embryo evaluation workflow using artificial intelligence <b>Simon Cooke</b> , Scientific Director of IVF Australia	
iDAScore behind the scenes : Towards fully automatic embryo evaluation <b>Jens Rimstad</b> , Deep Learning specialist, Vitrolife	
Experiences evaluating Vitrolife AI solutions for embryo evaluation <b>Tony Price</b> , Embryology Manager at Wessex Fertility Clinic, UK	
Discussion	
<b>17:45-19:15</b>	<b>Session 4: Progesterone in ART</b>
The pharmacodynamics and safety of progesterone in ART, what clinicians should know <b>Paul Piette</b> , Belgium	
Progesterone S.C. for luteal phase support in IVF treatment – an excellent opportunity <b>Dominique de Ziegler</b> , France	
The role of progestin in the luteal support treatment <b>George Griesinger</b> , Germany	
Discussion	
<b>19:15-21:30</b>	<b>Session 5: The oocyte and the mitochondria: laboratory and clinical aspects</b> Moderator: <b>Gerald Schatten</b> , USA
Introduction: Is there paternal mtDNA leakage during Reproduction and maternal mtDNA reversal after Nuclear and/or Spindle Transfer? <b>Gerald Schatten</b> , USA	
The oocyte and the mitochondria – clinical perspective <b>Gustavo Nardini Cecchino</b> , Brazil	
Clinical aspects of Nuclear Transfers <b>Valery Zukin</b> , Ukraine	
Heteroplasmy level after Nuclear Transfers - from embryo to the newborn <b>John Zhang</b> , USA	
Embryologic aspects of Nuclear Transfers <b>Pavlo Mazur</b> , Ukraine	
Discussion	



# 3<sup>rd</sup> IVF Worldwide Online Congress: Optimizing IVF treatment to maximize the likelihood of conception

14:00-22:00 CEST

## PRELIMINARY PROGRAM

<b>Saturday, April 3, 2021</b>	
14:00- 15:15	<b>Session 6: State of the ART 2021 (Organized by the Editors of RBMOnline)</b> Moderator: <b>Bart Fauser</b> , The Netherlands
Introduction <b>Bart Fauser</b> , The Netherlands	
Oncofertility <b>Richard Anderson</b> , UK	
Endocrine treatments of endometriosis and adenomyosis <b>Felice Petraglia</b> , Italy	
Infertility treatment in PCOS <b>Bart Fauser</b> , The Netherlands	
Conclusion <b>Bart Fauser</b> , The Netherlands	
Discussion	
15:15-16:15	<b>Session 7: AI in reproductive medicine, what should we need to know about?</b>
What you need to know about "Integrated Practice" in your IVF Unit in order to coordinate hundreds of data points to improve your IVF success rate <b>Markus Kupka</b> , Germany	
AI and machine learning in ART: The process and how it will enhance clinical decision making for doctors <b>Dean Morbeck</b> , New Zealand	
Discussion	
16:15-17:15	<b>Session 8: The Growing Role of Ultrasound in Modern Reproductive Medicine. A GE Symposium</b>
How to Incorporate 3D Into IVF and Why it Matters <b>Nick Raine-Fenning</b> , UK	
The ART of Reproductive Medicine: New Technology and Automation for the Reproductive Endocrinologist <b>Angela Palumbo</b> , Spain	
Discussion	
17:15-18:30	<b>Session 9: Fertility preservation for social reasons</b> <i>Supported by an unrestricted educational grant by Merck Israel</i>
Controlled ovarian stimulation for social oocyte freezing <b>Ariel Weissman</b> , Israel	
Our experience with oocytes preservation for social reasons <b>Ana Cobo</b> , Spain	
Why are frozen oocytes still frozen? A five year follow up of women after social egg freezing <b>Avi Tsafirir</b> , Israel	
Discussion	
18:30-19:00	<b>Session 10: Special lecture: Hysteroscopy prior or after IVF</b> Moderator: <b>Moti Goldenberg</b> <i>Supported by an unrestricted educational grant by Karl Storz</i>
<b>Rudi Campo</b> , Belgium	
Discussion	



# 3<sup>rd</sup> IVF Worldwide Online Congress: Optimizing IVF treatment to maximize the likelihood of conception

14:00-22:00 CEST

## PRELIMINARY PROGRAM

19:00-20:20	<b>Session 11: Fertility preservation in cancer patients</b> <i>Supported by an unrestricted educational grant by Ferring Pharmaceuticals</i>
The European guideline for Fertility Preservation <b>Michael Grynberg</b> , France	
DuoStim - a reproducible strategy to obtain more oocytes and competent embryos in a short time-frame aimed at fertility preservation and IVF purposes <b>Alberto Vaiarelli</b> , Italy	
Our latest techniques and results of ovarian tissue cryopreservation <b>Marie-Madeleine Dolmans</b> , Belgium	
Discussion	
20:20-21:45	<b>Session 12: Ovarian response</b>
The role of AMH in reproductive medicine: A critical review <b>Human Fatemi</b> , Abu Dhabi/UAE	
The effectiveness of “rebounding” if patients do not respond at all to ovarian stimulation <b>Norbert Gleicher</b> , USA	
LH for ovulation induction <b>Robert Fischer</b> , Germany	
Discussion	
21:45-22:15	<b>Session 13: Special lecture: The place of the Surgery of the Uterine Cavity in the IVF outcome improvement</b> Moderator: Zeev Shoham, Israel
<b>Sergio Haimovich</b> , Israel	
22:15-22:45	<b>Session 14: Closing / Key lecture</b>
A case study: Unexplained implantation failure: PGT-a, ERA, Immuno-Modulation, and the microbiome <b>Milton Leong</b> , HK	
Closing remarks	